Warren Buffett famously said, ‘Volatility is far from synonymous with risk.’ It’s only natural to consider a company’s balance sheet when you examine how risky it is, since debt is often involved when a business collapses. We can see that Omnicell, Inc.<\/strong> (NASDAQ:OMCL<\/a>) does use debt in its business. But is this debt a concern to shareholders? <\/p>\n Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. When we think about a company’s use of debt, we first look at cash and debt together. <\/p>\n Check out our latest analysis for Omnicell <\/a><\/span><\/p>\n You can click the graphic below for the historical numbers, but it shows that as of September 2022 Omnicell had US$565.8m of debt, an increase on US$482.8m, over one year. However, it does have US$266.4m in cash offsetting this, leading to net debt of about US$299.4m. <\/p>\n We can see from the most recent balance sheet that Omnicell had liabilities of US$376.7m falling due within a year, and liabilities of US$667.6m due beyond that. Offsetting this, it had US$266.4m in cash and US$366.7m in receivables that were due within 12 months. So it has liabilities totalling US$411.2m more than its cash and near-term receivables, combined. <\/p>\n Since publicly traded Omnicell shares are worth a total of US$2.25b, it seems unlikely that this level of liabilities would be a major threat. Having said that, it’s clear that we should continue to monitor its balance sheet, lest it change for the worse. <\/p>\n We measure a company’s debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio). <\/p>\n With a debt to EBITDA ratio of 2.3, Omnicell uses debt artfully but responsibly. And the fact that its trailing twelve months of EBIT was 7.3 times its interest expenses harmonizes with that theme. Shareholders should be aware that Omnicell’s EBIT was down 33% last year. If that earnings trend continues then paying off its debt will be about as easy as herding cats on to a roller coaster. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Omnicell’s ability to maintain a healthy balance sheet going forward. So if you’re focused on the future you can check out this free<\/strong> report showing analyst profit forecasts<\/a>. <\/p>\n But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So it’s worth checking how much of that EBIT is backed by free cash flow. Over the last three years, Omnicell actually produced more free cash flow than EBIT. There’s nothing better than incoming cash when it comes to staying in your lenders’ good graces. <\/p>\n Omnicell’s EBIT growth rate was a real negative on this analysis, although the other factors we considered were considerably better. There’s no doubt that its ability to to convert EBIT to free cash flow is pretty flash. It’s also worth noting that Omnicell is in the Medical Equipment industry, which is often considered to be quite defensive. Considering this range of data points, we think Omnicell is in a good position to manage its debt levels. But a word of caution: we think debt levels are high enough to justify ongoing monitoring. There’s no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet – far from it. Be aware that Omnicell is showing 3 warning signs in our investment analysis<\/strong> <\/a>, you should know about… <\/p>\n At the end of the day, it’s often better to focus on companies that are free from net debt. You can access our special list of such companies<\/a> (all with a track record of profit growth). It’s free. <\/p>\n What are the risks and opportunities for Omnicell?<\/p>\n What Risk Does Debt Bring? <\/h2>\n
What Is Omnicell’s Net Debt? <\/h2>\n
<\/a>
A Look At Omnicell’s Liabilities <\/h2>\n
Our View<\/h2>\n